|
Third
International Symposium
Toward the rapid assessment of therapy efficacy
CREMONA (Italy) 30th September, 1st - 2nd October 2007
Azienda Ospedaliera
Istituti Ospitalieri di Cremona
Dipartimento Provinciale di Oncologia
Dipartimento Provinciale di Chirurgia
Unità di Patologia Mammaria Breast Unit
Azienda Ospedaliera
San Luigi di Orbassano
Università degli Studi di Torino
Dipartimento di Scienze Cliniche e Biologiche Oncologia Medica
SYMPOSIUM LOCATION
Palazzo Cittanova - C.so Garibaldi, 135 - CREMONA: map
here!
HONONARY PRESIDENTS
P. Alquati
AO Istituti Ospitalieri, Cremona (Italy)
G. Bonadonna
INT - Istituto Nazionale Tumori, Milano (Italy)
PRESIDENTS
A. Bottini
Breast Unit - AO Istituti Ospitalieri, Cremona (Italy)
L. Dogliotti
ASO San Luigi, Orbassano, Torino (Italy)
Università degli Studi di Torino
Dipartimento di Scienze Cliniche e Biologiche
Oncologia Medica
S. B. Fox
Peter MacCallum Cancer Center, Melbourne (Australia)
A. L. Harris
WIMM - Institute of Molecular Medicine
University of Oxford (UK)
SCIENTIFIC COORDINATORS
M. Aglietta - IRCCS, Candiolo, Torino (Italy)
A. Berruti - ASO San Luigi, Orbassano, Torino (Italy)
F. Boccardo - Ist. Naz. Ricerca Cancro, Genova (Italy)
L. Gianni - INT - Istituto Nazionale Tumori, Milano (Italy)
W. R. Miller - Breast Unit, Edinburgh (UK)
SCIENTIFIC SECRETARIAT
S. Bonardi
Breast Unit - AO Istituti Ospitalieri, Cremona (Italy)
Phone +39 0372 405172/1 - Fax +39 0372 405307
simon.bonardi@tiscali.it
M. P. Brizzi
ASO San Luigi, Orbassano, Torino (Italy)
Phone +39 011 9026512 - Fax +39 011 9026992
mariapia.brizzi@email.it
ORGANIZING SECRETARIAT
Over Media Consult Srl
Via Manini 31 - 26100 Cremona
Phone +39 0372 23310 Fax +39 0372 569605
www.overconsult.it
info@overconsult.it
federica.signori@overconsult.it
HEALTH VISITOR AND HEALTH
PROMOTION FOR CANCER DETECTION
Aim: The diagnosis of cancer is a critical moment
for patients and their relatives. This dramatic
situation requires an increasing number of
specialists in health promotion, working together
with surgeons and oncologists. An up-date of
strategies for cancer prevention and an
establishment of dedicated equipe for counselling
in oncology are warranted. The meeting wants to
highlight the importance of health figures as
fundamental key-persons in epidemiological and
social-care research and prevention programs for a
Breast Cancer Unit.
The meeting is addressed to: health visitors, nurses
and other professional operators involved in
cancer management
Primary
systemic anti-neoplastic treatment is
increasingly adopted either in clinical trials or daily
routine as a part of the multidisciplinary approach
of both operable and locally advanced breast
cancers. This treatment modality represents a
formidable tool to test in vivo the tumour
sensitivity to a selected therapeutic approach; it
also allows to explore the interaction between
anti-neoplastic therapy and tumour biology, and
can provide surrogate parameters of treatment
efficacy. The Unità di Patologia Mammaria – Breast
Cancer Unit of Azienda “Istituti Ospitalieri di
Cremona” , collaborating with the University of
Turin (Italy), the University of Oxford (United
Kingdom), the University of Melbourne (Australia),
is organising the Third International Symposium in
order to highlight and discuss with leading experts
the status of the art and perspectives of primary
systemic treatment in the management of breast
cancer patients.
September 30th - Sunday
h 13.30 Registration
h 13.45 Satellite symposiums
Chairmen: A. Bottini, L. Dogliotti, A.L. Harris
h 17.45 Welcome speech
h 18.00 Round table: The requirements of a
specialist Breast Unit
A. Bottini, L. Cataliotti, R. E. Mansel, W. R. Miller,
M. Rosselli Del Turco
h 19.00 Introductory Lecture
Evolving role of primary systemic
treatment
L. Gianni
h 19.30 Opening Ceremony and Welcome Party
October
1st - Monday
SESSION I
State of the art and perspectives
Chairmen: W.R. Miller, P. Pronzato
h 08.30 Interacting questions
M. P. Brizzi, E. Milani
h 09.00 Overview on chemotherapy: concomitant
or sequential?
P. Valagussa
h 09.20 Overview on endocrine therapy
F. Montemurro
h 09.40 Is concomitant endocrine and chemotherapy
detrimental? The Cremona Breast Unit
experience
A. Berruti, A. Bottini
h 10.00 Evolving role of surgical treatment in
primary chemotherapy
R. Mansel
h 10.20 Questions and Discussion
h 10.40 Coffee Break
Chairmen: L. Dogliotti, L. Gianni, A.L. Harris
h 11.00 Selected oral communications
h 11.30 Special comunication: The role of
dose-dense in neo-adjuvant setting
M. Danova
h 12.00 Keynote lecture: New approaches in
neo-adjuvant: role of target therapies
R. I. Nicholson
h 12.30 Lunch
SESSION II
Surrogate parameters: How can we rapidly
assess the treatment efficacy?
Chairmen: P.F. Conte, M. Papotti
h 14.00 Pathological Complete Response (pCR):
Different international classifications
S.B. Fox
h 14.20 Biological predictive variables of pCR
S. Bonardi
h 14.40 Are there any survival differences between
pCR and DCIS?
A. Makris
h 15.00 Is pCR a surrogate marker of treatment
efficacy?
Pro: G. von Minckwitz
Contra: P. Bruzzi
h 15.30 Discussion
h 15.45 Coffee Break
Chairmen: M. Aglietta, F.Boccardo
h 16.00 MRI: detection tumour biology changes
under treatment
A. Padhani
h 16.20 PET and breast scintigraphy: applications in
primary therapy?
E. Bombardieri
h 16.40 Early response as a guide for further
treatment
M. Kaufmann
h 17.00 Discussion
h 17.20 Keynote lecture: Tumour microenvironment
and its relation to the therapy
M.I. Koukourakis
h 17.50 ARIA Symposium (Associazione per la
Ricerca tra Italia e Australasia, Italian-
Australian Research Association)
The role of Italian Government in supporting
bilateral projects
N. Sassanelli
ARIA in Queensland
D. Kennedy
h 18.00 kConFab: The Australian consortium
facilitating international breast cancer
research
H. Thorne
October
2nd - Tuesday
SESSION III
Treatment interaction with tumour biology:
finding strategies to overcome resistance with target therapies?
Chairmen: A. Bersiga, S. Fox,
h 09.00 Therapeutic resistance mechanisms
J.C. Chang
h 09.20 Protein expression profile in neo-adjuvant
setting
D.G. Generali
h 09.40 Clinical application of gene and protein
expression profile in breast cancer treatment
C. Sotiriou
h 10.00 Coffee Break
Chairmen: A Bottini, L Dogliotti
h 10.20 Markers of chemo-resistance
G. Tortora
h 10.40 Markers of endocrine-resistance
W.R. Miller
h 11.00 Target therapy as an overcoming
treatment tool
G. Gasparini
h 11.20 Pharmacogenomics as an identifier
method for target therapy
L. Pusztai
h 11.40 Questions and Discussion
Chairmen: S. Barni, A. Berruti, R. Passalacqua
h 12.00 Selected Oral Communications
h 12.30 Keynote lecture: Clinical impact of hypoxia
in the management of breast cancer
A.L. Harris
h 13.00 Ending Ceremony and lunch
h 18.20 Biological background for immunotherapy
in breast cancer
D. Kennedy
h 18.40 Immunomodulating effect of aromatase
inhibitor in breast cancer. A bilateral project
S.B. Fox
Organizzazione
Congressi
Over
Consult
Via Pagliari 8 Cremona
Phone +39.0372.23310
Fax +39.0372.569605
info@overconsult.it
|
